Leader Health, a cutting-edge technology enterprise dedicated to providing automated, intelligent, and system-level solutions for the life science instruments and biopharmaceutical sectors, has recently announced the successful completion of its Pre-A++ round financing, raising tens of millions of yuan. This latest funding achievement follows closely on the heels of its earlier rounds, having already secured tens of millions of yuan in Pre-A round financing and over 100 million yuan in Pre-A+ round financing in 2026. Strategically invested in by Shanghai International Group Investment Co., Ltd., with WinX Capital acting as the exclusive financial advisor, this round of financing is poised to propel Leader Health to new heights.

The funds raised in this round will be primarily allocated to bolstering business deployment/expansion in the East China region, recruiting top-tier talent, accelerating the development of high-end scientific instruments and AI for Science business, enhancing production capabilities, and expanding national market channels. These strategic moves are expected to further deepen services for customers in the Yangtze River Delta region and solidify Leader Health's leading position in the field of AI life science instruments and biomanufacturing equipment digital intelligence platforms.

Zhang Feng, the founder and CEO of Leader Health, along with relevant leaders from WinX Capital, shared their insights on this financing round and the company's future development trajectory. Leader Health reiterated its commitment to increasing R&D investment, tackling technical challenges in the high-end scientific instrument domain, promoting automation and intelligent transformation within the life science sector, facilitating the high-quality development of AI for Science, and ultimately striving towards the noble goal of 'contributing to human health and longevity'.